Oct 10, 2024 8:00am EDT Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting
Oct 01, 2024 8:45am EDT Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs
Aug 26, 2024 4:30pm EDT Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors
Aug 13, 2024 4:01pm EDT Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
Jul 31, 2024 8:00am EDT Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
Jul 29, 2024 8:00am EDT Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
Jul 25, 2024 8:00am EDT Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
Jul 01, 2024 8:00am EDT Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
May 29, 2024 8:00am EDT Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes